About Surfeit locus protein 1
Surfeit locus protein 1 (SURF1) is a protein
from Homo sapiens identified by UniProt accession
Q15526, 300 residues long.
MolForge cross-references it against 0 known binders and
120 disease associations.
Target properties
| Protein name | Surfeit locus protein 1 |
|---|
| UniProt accession | Q15526 |
|---|
| Gene | SURF1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 300 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (120)
Diseases linked to this target (Open Targets).
- Leigh syndrome · score 0.79
- Isolated cytochrome C oxidase deficiency · score 0.72
- Charcot-Marie-Tooth disease type 4K · score 0.71
- leigh syndrome due to mitochondrial complex iv deficiency · score 0.57
- mitochondrial complex IV deficiency, nuclear type 22 · score 0.57
- genetic disorder · score 0.52
- SURF1-related Charcot-Marie-Tooth disease type 4 · score 0.46
- mitochondrial disease · score 0.43
- Muscle weakness · score 0.41
- Dysarthria · score 0.41
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q15526-F1 | alphafold | PREDICTED | 81.39 | — |
Amino-acid sequence (300 residues)
MAAVAALQLG LRAAGLGRAP ASAAWRSVLR VSPRPGVAWR PSRCGSSAAE ASATKAEDDS FLQWVLLLIP VTAFGLGTWQ VQRRKWKLNL IAELESRVLA EPVPLPADPM ELKNLEYRPV KVRGCFDHSK ELYMMPRTMV DPVREAREGG LISSSTQSGA YVVTPFHCTD LGVTILVNRG FVPRKKVNPE TRQKGQIEGE VDLIGMVRLT ETRQPFVPEN NPERNHWHYR DLEAMARITG AEPIFIDANF QSTVPGGPIG GQTRVTLRNE HLQYIVTWYG LSAATSYLWF KKFLRGTPGV
Explore Surfeit locus protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets